For adults with Multiple Myeloma who have received at least 2 prior treatments
Going progression free longer means going longer without your Multiple Myeloma getting worse
In a clinical study, SARCLISA given with Pomalyst® (pomalidomide) and dexamethasone (Pd) extended the time people lived without their multiple myeloma getting worse compared to Pd alone (median of 11.5 months vs 6.5 months).
SARCLISA was
proven in a Phase 3 study.
SARCLISA is a targeted
immunotherapy that works
together with your
immune system.
Answer 7 short questions
to find out if SARCLISA
could be appropriate for you.